Summary & Overview
HCPCS G0477: Presumptive Drug Test Read by Direct Optical Observation
HCPCS Level II code G0477 denotes a presumptive drug test using devices or procedures readable by direct optical observation (such as dipsticks, cups, cards, or cartridges) and includes sample validation when performed, billed per date of service. The code captures point-of-care immunoassay testing that provides rapid, qualitative results for multiple drug classes and is commonly used in clinical, occupational, and screening contexts. Nationally, accurate coding of presumptive drug testing affects clinical workflows, laboratory billing classification, and oversight of substance-use screening programs.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of where and how G0477 is applied, typical sites of service, and the clinical context for presumptive immunoassay testing. The publication also outlines payer coverage considerations, common modifiers when reported, and how G0477 relates to confirmatory testing pathways and laboratory services.
This summary provides benchmarks for use of HCPCS Level II code G0477, highlights policy and coding considerations that affect billing and claims adjudication at a national level, and situates the code within care settings that rely on rapid, visually read drug screening.
Billing Code Overview
HCPCS Level II code G0477 describes a presumptive drug test for any number of drug classes using devices or procedures that are readable by direct optical observation only (for example, dipsticks, cups, cards, cartridges). The code covers performance of the presumptive test and includes sample validation when performed, billed per date of service.
Service type: Point-of-care presumptive drug screening.
Typical site of service: Outpatient settings and point-of-care locations where visually read immunoassay devices are used (for example, clinic offices, urgent care centers, workplace testing sites, and some laboratory collection points).
Clinical & Coding Specifications
Clinical Context
A 32-year-old patient presents to an outpatient substance use disorder clinic for routine monitoring of medication-assisted treatment. The clinician orders a presumptive urine drug screen performed on the date of service to detect recent use of opioids, benzodiazepines, amphetamines, cocaine, and cannabinoids. A medical assistant collects the specimen, performs point-of-care immunoassay testing using multi-panel dipsticks, documents results in the medical record, and includes sample validity checks (temperature, adulteration) when performed. The result is reviewed by the treating clinician during the same visit to guide counseling and next-step treatment planning. Typical sites of service include outpatient clinics, physician offices, federally qualified health centers, urgent care centers, and addiction treatment programs. The service is non-quantitative, device-read by direct optical observation, and billed once per date of service using G0477 with appropriate technical component modifier when applicable.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
TC | Technical component — equipment, supplies, and technical personnel | Use when billing an entity that performed only the technical portion of the presumptive drug test (laboratory or clinic equipment and staff) and the professional interpretation is billed separately. |